## Vitaly Omelyanovsky

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7938047/publications.pdf

Version: 2024-02-01

1478505 1372567 54 108 10 6 citations h-index g-index papers 56 56 56 106 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Economic evaluation of therapeutic education (in diabetes school) for patients with type 1 and type 2 diabetes mellitus. Medical Technologies Assessment and Choice (ĐœĐμĐĐ¸Ñ†Đ¸Đ½NаиĐμ Ñ,ĐμÑĐ½Đ¾Đ»E	94 <b>4</b> 3Đ,Đ,	ĐžÑ†ĐμĐ½
2	Key business processes in healthcare and their readiness for digital transformation. Medical Technologies Assessment and Choice (ĐœĐμĐ Đ,цĐ,Đ½ÑĐºĐ,Đμ Ñ,ĐμÑĐ½Đ³¾Đ»Đ³¾Đ³Đ,Đ, ĐžÑ†ĐμĐ½Đ°Đ°Đ	° <mark>°</mark> 5,⁴Đ²Ñ‹E	) <del>2</del> Đ¾Ñ€), 2(
3	Economic evaluation of providing patients with test strips for blood glucose level monitoring with a frequency indicated in clinical guidelines in the Russian Federation. Medical Technologies Assessment and Choice (ĐœĐμĐĐ,цĐ,Đ½ÑаĐ,Đμ Ñ,ĐμÑĐ½Đ³ΔĐ»Đ¾ĐĐĐ,Đ ĐžÑ†ĐμĐ½Đ°Đ° и Đ²ÑæĐ±Đ¾Ñ€), 2022,	0.4 , 42.	O
4	Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation. Farmakoekonomika, 2022, 15, 5-22.	1.2	1
5	Main changes in the model of diagnosis-related groups in 2022. Medical Technologies Assessment and Choice (ĐœĐμĐ Đ,цĐ,Đ½ ÑаĐ,Đμ Ñ,ĐμÑĐ½ Đ¾ Đ»Đ¾ Đ3Đ,Đ, ĐžÑ†ĐμĐ½ аа Đ, Đ² Ñ∢Đ±Đ¾ Ň€), 2022, 44,	8. <sup>4</sup>	3
6	Determination of incremental cost-effectiveness ratios of antitumor drugs. Farmatsiya-Moscow, 2021, 70, 40-45.	0.1	0
7	Development of a method for calculation of demand for medical personnel in the healthcare of the Russian Federation, using a mathematical model. Farmakoekonomika, 2021, 13, 427-437.	1.2	0
8	Concept of value-based healthcare. Farmakoekonomika, 2021, 13, 438-451.	1.2	7
9	Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system. Farmakoekonomika, 2021, 13, 367-376.	1.2	9
10	Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy. Farmakoekonomika, 2021, 14, 5-15.	1.2	1
11	Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology, 2021, 26, 4490.	1.4	19
12	Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis by means of sublingual allergen-specific immunotherapy. Russian Journal of Allergy, 2021, 18, 5-17.	0.2	0
13	Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871. Farmakoekonomika, 2020, 13, 113-123.	1.2	10
14	The health technology assessment system in Australia. Farmakoekonomika, 2020, 12, 333-341.	1.2	0
15	MEDICAL CARE FOR HEMORRHOIDS IN THE FEDERAL SUBJECTS OF RUSSIA IN 2018. Koloproktologia, 2020, 19, 126-134.	0.6	2
16	Affordability of in vivo gene therapy. Problems and potential solutions. Farmakoekonomika, 2020, 13, 170-182.	1.2	0
17	Evolution of healthcare provider payment mechanisms. Farmakoekonomika, 2020, 12, 318-326.	1.2	3
18	Drug provision and health technology assessment in France. Farmakoekonomika, 2020, 13, 71-83.	1.2	0

#	Article	IF	CITATIONS
19	Parameters for evaluating the main indicators of coloproctological care in the adult population in the subjects of the far Eastern Federal District in 2016–2018. Farmakoekonomika, 2020, 13, 240-250.	1.2	1
20	Regulatory framework of the oncological medical care provision. Farmakoekonomika, 2020, 13, 304-315.	1,2	3
21	The review of the foreign experience on the financing of innovative medical technologies. Farmakoekonomika, 2020, 13, 316-323.	1.2	1
22	Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making. Farmakoekonomika, 2020, 13, 262-269.	1.2	1
23	Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense. Farmakoekonomika, 2019, 11, 81-91.	1.2	0
24	International experience in determining the cost-effectiveness thresholds. Farmakoekonomika, 2019, 11, 73-80.	1.2	1
25	Organizational structure and funding of health technology assessment agencies around the world. Farmakoekonomika, 2019, 12, 146-154.	1.2	1
26	Health technology assessment and reimbursement of pharmaceuticals in Italy. Farmakoekonomika, 2019, 12, 156-164.	1,2	1
27	Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019. Farmakoekonomika, 2019, 12, 169-177.	1.2	0
28	Diabetes mellitus as an economic problem in Russian Federation. Diabetes Mellitus, 2016, 19, 30-43.	1,9	17
29	Direct Costs of Unintended Pregnancy in the Russian Federation. Applied Health Economics and Health Policy, 2015, 13, 61-68.	2.1	4
30	The Cost of Melanoma and Kidney, Prostate, and Ovarian Cancers in Russia. Value in Health Regional Issues, 2014, 4, 58-65.	1,2	4
31	Mcda Approach To Ranking Rare Diseases In Russia: Preliminary Results. Value in Health, 2014, 17, A539.	0.3	9
32	Efficiency Of Rehabilitation Programs For Patients After Traumatic Brain Injury And Acute Cerebrovascular Accident (Stroke) In Russia. Value in Health, 2014, 17, A490.	0.3	0
33	Fixed Dose Combinations of Nucleoside Reverse Transcriptase Inhibitor for NaÃ-ve Patient with Hiv Infection in Russia: Cost Comparison Analysis. Value in Health, 2014, 17, A669.	0.3	0
34	Cost-Effectiveness Analysis Of Antiviral Pharmacotherapies For Treatment Of Chronic Hepatitis C Virus Infection In Russia. Value in Health, 2014, 17, A366-A367.	0.3	0
35	Estimating the Costs of Drug Supply for Rare Diseases Patients In Russia. Value in Health, 2014, 17, A525.	0.3	0
36	Potential Economic Impact of Using Sugammadex for the Routine Reversal of Neuromuscular Blockade in Russian Health Care Setting. Value in Health, 2013, 16, A558-A559.	0.3	0

#	Article	IF	CITATIONS
37	Cost-Minimization Analysis of Maraviroc Versus Darunavir Raltegravir and Enfuvirtide for CCR5-Tropic Treatment-Experienced Patients with HIV Infection in Russia. Value in Health, 2013, 16, A358-A359.	0.3	0
38	Pharmacoeconomic Evaluation of the Fixed-Dose Combination of Abacavir/Lamivudine in the Antiretroviral Therapy of NaÃ-ve HIV Infected Patients in Russia. Value in Health, 2013, 16, A345-A346.	0.3	0
39	Costs Associated with Cold Chain Used to Store and Transport Thermally Unstable Antiretroviral Drugs. Value in Health, 2013, 16, A360.	0.3	0
40	Comparative Economic Analysis of Retreatment Strategies for HCV Genotype 1 Patients in Russia. Value in Health, 2013, 16, A498.	0.3	0
41	The Cost of Specialized Hospital Care for Patients with Diabetic Foot Ulcers in Russia. Value in Health, 2013, 16, A444.	0.3	0
42	PRS23 Pharmacoeconomic Analysis of Roflumilast for Treatment of Adult Patients With Severe-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD). Value in Health, 2012, 15, A563.	0.3	0
43	PIH12 Burden of Early-Onset Neonatal Sepsis in the Russian Federation. Value in Health, 2012, 15, A538.	0.3	O
44	PCN49 Economic Burden of Melanoma in Russia. Value in Health, 2012, 15, A417.	0.3	1
45	PCN57 Economic Burden of Prostate Cancer in Russia. Value in Health, 2012, 15, A419.	0.3	0
46	PMS16 Economic Burden of Juvenile Idiopathic Arthritis in Russia. Value in Health, 2012, 15, A442.	0.3	0
47	PUK17 Cost-Mimimization Analysis of Pazopanib Versus Sunitinib, Sorafenib and Bevacizumab+ Interferon $\tilde{A}_i$ -2a for Patients With Metastatic Renal Cell Carcinoma. Value in Health, 2012, 15, A458.	0.3	0
48	PCN97 Pharmacoeconomic Analysis of the Prostate Cancer Therapy with Gonadotropin-Releasing Hormone Analogues: Leuprorelin, Goserelin, Triptorelin. Value in Health, 2012, 15, A426-A427.	0.3	0
49	PRS42 Pharmacoeconomic Analysis of Methylprednisolone Aceponate for Treatment of Atopic Dermatitis and Eczema. Value in Health, 2011, 14, A495.	0.3	1
50	PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia. Value in Health, 2011, 14, A277-A278.	0.3	0
51	PCV17 Cost-Effectiveness Analysis of Bosentan and Sildenafil Compared with Standard therapy in Treatment of Primary Pulmonary Arterial Hypertension in Russian Federation. Value in Health, 2011, 14, A367.	0.3	0
52	PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis. Value in Health, 2011, 14, A506.	0.3	0
53	PCN53 ANALYSIS OF SOCIOECONOMIC BUREDN OF HEPATOCELLULAR CARCINOMA IN RUSSIA. Value in Health, 2010, 13, A260-A261.	0.3	O
54	PRS21 BURDEN OF BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN RUSSIA. Value in Health, 2010, 13, A322.	0.3	0